Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | HTR2B | P41595 | 3/20 | 0.45 |
| ▸ | PNMT | P11086 | 4/20 | 0.42 |
| ▸ | HTR5A | P47898 | 4/20 | 0.41 |
| ▸ | HTR3A | P46098 | 3/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 2/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585704 | 0.82 | HTR2A (0.48) | HTR2AHTR2CHTR2BPNMTHTR5A | |
| SCHEMBL2301407 | 0.82 | HTR2A (0.48) | HTR2AHTR2CHTR2BPNMTHTR5A | |
| SCHEMBL577820 | 0.75 | DRD2 (0.41) | DRD4 | |
| SCHEMBL17278199 | 0.73 | HTR2A (0.39) | HTR2AHTR2CHTR2BPNMTHTR5A | |
| SCHEMBL6904514 | 0.70 | HTR2A (0.50) | HTR2AHTR2CHTR2BPNMTMETAP1 | |
| SCHEMBL15962624 | 0.70 | — | — | |
| SCHEMBL585896 | 0.70 | HTR5A (0.41) | HTR5AADRA2AADRA2BADRA2CNOTUM | |
| SCHEMBL577455 | 0.70 | PNMT (0.42) | PNMTADRA2AADRA2BADRA2CMETAP1 | |
| SCHEMBL5539314 | 0.70 | PNMT (0.42) | PNMTADRA2AADRA2BADRA2C | |
| Ammonia Solution, Strong SCHEMBL1325642 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | claimed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | claimed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | claimed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2008118758-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (GB) | 2008-10-02 | — | — | WO | claimed |
| EP-0220917-B1 | 1,4-DIHYDROPYRIDINE PHARMACEUTICAL DERIVATIVES AND THEIR SALTS, AND THE PREPARATION THEREOF | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1991-01-30 | — | — | EP | claimed |
| EP-0280239-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVES, PRODUCTION AND USE THEREOF | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1990-07-04 | — | — | EP | claimed |
| EP-0280239-A1 | 1,4-Dihydropyridine derivatives, production and use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1988-08-31 | — | — | EP | claimed |
| EP-0220917-A1 | 1,4-Dihydropyridine pharmaceutical derivatives and their salts, and the preparation thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1987-05-06 | — | — | EP | claimed |
| US-9284307-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-8993595-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0220917-B1 | 1,4-DIHYDROPYRIDINE PHARMACEUTICAL DERIVATIVES AND THEIR SALTS, AND THE PREPARATION THEREOF | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1991-01-30 | — | — | EP | disclosed |
| EP-0280239-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVES, PRODUCTION AND USE THEREOF | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1990-07-04 | — | — | EP | disclosed |
| US-4824855-A | CALCIUM ANTAGONIST, VASODILATORS | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1989-04-25 | — | — | US | disclosed |
| EP-0280239-A1 | 1,4-Dihydropyridine derivatives, production and use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1988-08-31 | — | — | EP | disclosed |
| EP-0220917-A1 | 1,4-Dihydropyridine pharmaceutical derivatives and their salts, and the preparation thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | HTR2A 1246/4885HTR2C 773/4885HTR2B 630/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | HTR2A 1246/4885HTR2C 773/4885HTR2B 630/4885 |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | HTR2A 3619/4885HTR2C 3113/4885HTR2B 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.